LTF and Alzheimer disease: Other AMPs (e.g., lactoferrin) reduce the levels of key players of inflammation and oxidative stress involved in AD pathology and can also promote the non-amyloidogenic metabolism of APP processing through activation of the α-secretase pathway, leading to the production of neuroprotective soluble sAPPα.